Nigeria calls Pfizer execs to trial

Nigeria v. Pfizer in the matter of a meningitis vaccine trial went back to court today, with a judge allowing the authorities there to summon Pfizer and nine company officials to the country to defend themselves. The summons aims to compel the execs to a hearing November 6.

Civil rights groups are all set to protest against the drug maker, which is criminally and civilly accused misconduct when it tried out its Trovan treatment during a 1996 meningitis epidemic. Eleven children participating in the trial died, and others ended up with permanent injuries. Pfizer denies wrongdoing, saying it answered pleas for help when it brought the experimental drug to Nigeria.

Trovan, of course, proved a safety risk when it was licensed by the FDA a few months after the Nigerian trial. Three years later, the agency restricted the drug because of possible liver damage.

- read the article from the International Business Times
- see this item from the Wall Street Journal

Related Articles:
Pfizer seeks dismissal of Nigeria lawsuit. Report
Trial deaths spur criminal charges against Pfizer. Report
Pfizer 'exploited' children in African trial. Report
Report: Pfizer 'exploited' children in African trial. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.